IL205613A - Triazolo [5,4– d] pyrimidine compounds for the treatment of aortic aneurysm - Google Patents

Triazolo [5,4– d] pyrimidine compounds for the treatment of aortic aneurysm

Info

Publication number
IL205613A
IL205613A IL205613A IL20561310A IL205613A IL 205613 A IL205613 A IL 205613A IL 205613 A IL205613 A IL 205613A IL 20561310 A IL20561310 A IL 20561310A IL 205613 A IL205613 A IL 205613A
Authority
IL
Israel
Prior art keywords
triazolo
treatment
abdominal aortic
pyrimidine compounds
aortic aneurysms
Prior art date
Application number
IL205613A
Other languages
English (en)
Hebrew (he)
Other versions
IL205613A0 (en
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IL205613A0 publication Critical patent/IL205613A0/en
Publication of IL205613A publication Critical patent/IL205613A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL205613A 2007-12-03 2010-05-06 Triazolo [5,4– d] pyrimidine compounds for the treatment of aortic aneurysm IL205613A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07301616 2007-12-03
PCT/SE2008/051386 WO2009072967A1 (en) 2007-12-03 2008-12-02 Triazolo [4,5-d] pyrimidine compounds for treatment of abdominal aortic aneurysms

Publications (2)

Publication Number Publication Date
IL205613A0 IL205613A0 (en) 2010-11-30
IL205613A true IL205613A (en) 2015-04-30

Family

ID=40717966

Family Applications (1)

Application Number Title Priority Date Filing Date
IL205613A IL205613A (en) 2007-12-03 2010-05-06 Triazolo [5,4– d] pyrimidine compounds for the treatment of aortic aneurysm

Country Status (24)

Country Link
US (2) US20100298350A1 (enExample)
EP (1) EP2229172B1 (enExample)
JP (1) JP5701060B2 (enExample)
KR (1) KR101563757B1 (enExample)
CN (2) CN101883565A (enExample)
AU (1) AU2008331984B2 (enExample)
BR (1) BRPI0819458A2 (enExample)
CA (1) CA2707488C (enExample)
CY (1) CY1115760T1 (enExample)
DK (1) DK2229172T3 (enExample)
EA (1) EA201000928A1 (enExample)
ES (1) ES2522317T3 (enExample)
HR (1) HRP20141081T1 (enExample)
IL (1) IL205613A (enExample)
MX (1) MX2010006101A (enExample)
MY (1) MY159656A (enExample)
NZ (1) NZ585513A (enExample)
PL (1) PL2229172T3 (enExample)
PT (1) PT2229172E (enExample)
RS (1) RS53635B1 (enExample)
SI (1) SI2229172T1 (enExample)
UA (1) UA100864C2 (enExample)
WO (1) WO2009072967A1 (enExample)
ZA (1) ZA201003599B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102653539B (zh) * 2011-03-01 2014-09-17 秦引林 一种抗血小板聚集化合物及其药物组合
CN102924457A (zh) * 2011-08-12 2013-02-13 上海恒瑞医药有限公司 三唑并嘧啶类衍生物、其制备方法及其用途
EP2750676B1 (en) 2011-08-30 2018-01-10 University of Utah Research Foundation Methods and compositions for treating nephrogenic diabetes insipidus

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997003084A1 (en) * 1995-07-11 1997-01-30 Astra Pharmaceuticals Ltd. New inhibitors of platelet aggregation
AR017014A1 (es) * 1997-07-22 2001-08-22 Astrazeneca Ab Compuestos de triazolo [4,5-d]pirimidina, composiciones farmaceuticas, uso de los mismos para preparar medicamentos y procesos para la preparacionde dichos compuestos
TWI229674B (en) * 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
GB0013407D0 (en) * 2000-06-02 2000-07-26 Astrazeneca Ab Forms of a chemical compound
SE0101932D0 (sv) * 2001-05-31 2001-05-31 Astrazeneca Ab Pharmaceutical combinations
WO2009007675A2 (en) * 2007-07-11 2009-01-15 Cardoz Ab Combination for use in the treatment of atherosclerosis comprising a mast cell inhibitor and a p2 gamma 12 antagonist

Also Published As

Publication number Publication date
IL205613A0 (en) 2010-11-30
ES2522317T3 (es) 2014-11-14
PT2229172E (pt) 2014-11-03
SI2229172T1 (sl) 2014-12-31
WO2009072967A1 (en) 2009-06-11
EP2229172B1 (en) 2014-09-10
UA100864C2 (uk) 2013-02-11
HK1148195A1 (en) 2011-09-02
KR101563757B1 (ko) 2015-10-27
CA2707488A1 (en) 2009-06-11
ZA201003599B (en) 2012-10-31
NZ585513A (en) 2012-07-27
AU2008331984A1 (en) 2009-06-11
CN101883565A (zh) 2010-11-10
MX2010006101A (es) 2010-10-04
BRPI0819458A2 (pt) 2015-05-05
KR20100099175A (ko) 2010-09-10
HRP20141081T1 (hr) 2015-01-02
JP5701060B2 (ja) 2015-04-15
CY1115760T1 (el) 2017-01-25
PL2229172T3 (pl) 2015-01-30
DK2229172T3 (da) 2014-11-10
US20150272955A1 (en) 2015-10-01
EP2229172A4 (en) 2012-12-26
AU2008331984B2 (en) 2012-08-16
CA2707488C (en) 2015-07-28
EP2229172A1 (en) 2010-09-22
CN103919781A (zh) 2014-07-16
MY159656A (en) 2017-01-13
RS53635B1 (sr) 2015-04-30
EA201000928A1 (ru) 2010-12-30
JP2011505417A (ja) 2011-02-24
US20100298350A1 (en) 2010-11-25

Similar Documents

Publication Publication Date Title
IL204693A0 (en) Imidazo[1, 2 - a] pyrimidine derivatives for the treatment of diseases such as diabetes
ZA201004603B (en) 3h-[1,2,3]triazolo[4,5-d]pyrimidine compounds, their use as mtor kinase and p13 kinase inhibitors, and their synthesis
ZA201004368B (en) Pyrazolo [1,5-a] pyrimidines useful as jak2 inhibitors
IL248964A0 (en) Arterial supports for the treatment of arterial blockages in the body
IL194076A (en) Benzo Compounds - [d] - Imidzo [2, 1 – b] Thiazole-2-Ilphenyl for the Treatment of Illness
PL2001466T3 (pl) Rapamycyna w małej dawce do leczenia chorób związanych z przepuszczalnością naczyń
SI1904494T1 (sl) Imidazo(1,2-a)piridin spojine kot inhibitorji vegf-r2
WO2009024542A3 (en) Purin derivatives for use in the treatment of fab-related diseases
ZA200708591B (en) Pyrimidine derivatives for treatment of hyperproliferative disorders
IL206500A (en) Stero-selective processes for the preparation of sitagliptin
EP2225002A4 (en) RNA INTERFERENCE FOR THE TREATMENT OF CARDIAC SUFFICIENCIES
IL194522A0 (en) Process for the preparation of prasugrel
PT2024368E (pt) Derivados de 6,7,8,9-tetrahidro-5h-pirimido[4,5-d]azepina-4-il]-amina como moduladores de trpv1 para o tratamento da dor
IL206811A0 (en) NOVEL PYRAZOLO [3,4-d] PYRIMIDINE DERIVATIVES AS ANTI-CANCER AGENTS
IL201209A0 (en) Pyrido [2, 3 - d] pyrimidin - 7 - one compounds as inhibitors of pi3k - alpha for the treatment of cancer
IL196107A0 (en) PRODRUGS OF-5-AMINO-3-(3'-DEOXY-??-D-RIBOFURANOSYL)-THIAZOLO[4,5-d]PYRIMIDIN-2,7-DIONE
EP2142543B8 (en) Pyrido [2, 3-d]pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer
BRPI0822239A2 (pt) Composto de pirazolo[1,5-a] pirimidina
IL205613A0 (en) Triazolo [4,5-d]pyrimidine compounds for treatment of abdominal aortic aneurysms
IL187441A0 (en) Derivatives of 6,7-dihydro-5h-imidazo[1,2-a] imidazole-3-sulfonic acid
IL215521A0 (en) DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-a]IMIDAZOLE-3-CARBOXYLIC ACID AMIDES
GB2464854B (en) Process for the preparation of risperidone
GB2453005B (en) Macrocyclic tricothecene compounds for inhibiting the growth of cancer cells
IL200166A0 (en) New process for preparing 3-methyl-4-phenylisoxazolo[3,4-d]pyridazin-7(6h)-one
PT1962913E (pt) Radioimunoconjugado para cd66 humano para o tratamento de mieloma múltiplo

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed